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Human flavin-containing monooxygenase 3 (hFMO3) is a microsomal drug-metabolizing enzyme 
able to oxygenate drugs and xenobiotics containing a soft-nucleophile, usually sulphur or nitrogen. 
The structure of hFMO3 has not yet been solved and therefore molecular modelling was used in 
this work to assign a structural/functional role to the predicted secondary structure elements of the 
polypeptide sequence. A model of hFMO3 was built by combining ab-initio and homology 
modelling approaches using the structure of FMO from Methylophaga sp. as template (PDB ID: 
2VQ7) sharing a 30% sequence identity with the human counterpart. The energy minimized and 
refined model was used for docking experiments to show how known substrates bind the catalytic 
site of the enzyme. Based on the hydrophobic nature of the carboxyl terminus, it was hypothesized 
that this region could function as a membrane anchor. Therefore, a C-terminal truncated form of 
hFMO3 (tr-hFMO3) was engineered at DNA level and subsequently cloned, expressed in E. coli 
and purified in order to compare its solubility and activity with that of the full-length wild type 
enzyme. The tr-hFMO3 was purified from the cytosolic fraction whereas the wild type protein was 
purified from the membrane fraction. Furthermore, catalysis experiments with the tr-hFMO3 
showed that this enzyme is fully active and carries out the monooxygenation of substrates such as 
sulindac sulfide, benzydamine, tozasertib and danusertib. The results from docking experiments 
together with the success in rational design of the soluble and active tr-hFMO3 support the validity 
of the presented hFMO3 model. 
